Skip to main content
Top
Published in: Journal of Cancer Research and Clinical Oncology 8/2003

01-08-2003 | Original Paper

p21WAF1/CIP1 is more effective than p53 in growth suppression of mouse renal carcinoma cell line Renca in vitro and in vivo

Authors: Marijeta Kralj, Jasminka Pavelić

Published in: Journal of Cancer Research and Clinical Oncology | Issue 8/2003

Login to get access

Abstract

Purpose

Although there are many controversial reports about the effect of p53 and p21WAF1/CIP1 overexpression in different human tumor cells, the p53 gene is shown to be a more effective candidate for cancer gene therapy because of its more pronounced ability to induce apoptosis. In the present study, we present the effect of p53 and p21WAF1/CIP1 overexpression on mouse renal carcinoma cells in vitro and in vivo.

Methods

p53 and p21WAF1/CIP1 genes were introduced into Renca cells using adenoviral vectors (Ad5CMV-p53 and Ad5CMV-p21). The induction of apoptosis was measured using Annexin V assay and DNA fragmentation analysis. The expression of proteins was examined using immunocytochemistry and Western blot methods. The ability of adenoviral vectors to inhibit tumorigenicity of Renca cells, as well as the growth of pre-established tumors was measured.

Results

In vitro growth assays revealed higher growth suppression after Ad5CMV-p21 infection. Although both vectors induced apoptosis, Ad5CMV-p53 was slightly more efficient. In vivo studies in Balb/c mice, demonstrated that tumorigenicity was completely suppressed by Ad5CMV-p21. Besides this, Ad5CMV-p21 significantly inhibited the growth of established tumors, while Ad5CMV-p53 did not.

Conclusions

These data suggest that p21WAF1/CIP1 is a more potent growth suppressor than p53 of mouse tumor cells Renca. The divergent responses of tumor cells to p21WAF1/CIP1 overexpression could be due to various networks that differ between species.
Literature
go back to reference Cardinali M, Jakus J, Shah S, Ensley JF, Robbins KC, Yeudall WA (1998) p21(WAF1/CIP1) retards the growth of human squamous cell carcinomas in vivo. Oral Oncol 34:211–218CrossRefPubMed Cardinali M, Jakus J, Shah S, Ensley JF, Robbins KC, Yeudall WA (1998) p21(WAF1/CIP1) retards the growth of human squamous cell carcinomas in vivo. Oral Oncol 34:211–218CrossRefPubMed
go back to reference Clayman GL, Liu TJ, Overholt SM, Mobley SR, Wang M, Janot F, Goepfert H (1996) Gene therapy for head and neck cancer. Comparing the tumor suppressor gene p53 and a cell cycle regulator WAF1/CIP1 (p21). Arch Otolaryngol Head Neck Surg 122:489–493PubMed Clayman GL, Liu TJ, Overholt SM, Mobley SR, Wang M, Janot F, Goepfert H (1996) Gene therapy for head and neck cancer. Comparing the tumor suppressor gene p53 and a cell cycle regulator WAF1/CIP1 (p21). Arch Otolaryngol Head Neck Surg 122:489–493PubMed
go back to reference D'Orazi G, Marchetti A, Crescenzi M, Coen S, Sacchi A, Soddu S (2000) Exogenous wt-p53 protein is active in transformed cells but not in their non-transformed counterparts: implications for cancer gene therapy without tumor targeting. J Gene Med 2:11–21CrossRefPubMed D'Orazi G, Marchetti A, Crescenzi M, Coen S, Sacchi A, Soddu S (2000) Exogenous wt-p53 protein is active in transformed cells but not in their non-transformed counterparts: implications for cancer gene therapy without tumor targeting. J Gene Med 2:11–21CrossRefPubMed
go back to reference Dotto GP (2000) P21WAF1/CIP1: more than a break to the cell cycle. Biochim Biophys Acta 1471:M43-M56CrossRefPubMed Dotto GP (2000) P21WAF1/CIP1: more than a break to the cell cycle. Biochim Biophys Acta 1471:M43-M56CrossRefPubMed
go back to reference Duttaroy A, Qian J-F, Smith JS, Wang E (1997) Up-regulated p21CIP1 expression is part of the regulation quantitatively controlling serum deprivation-induced apoptosis. J Cell Biochem 64:434–446CrossRefPubMed Duttaroy A, Qian J-F, Smith JS, Wang E (1997) Up-regulated p21CIP1 expression is part of the regulation quantitatively controlling serum deprivation-induced apoptosis. J Cell Biochem 64:434–446CrossRefPubMed
go back to reference Eastham JA, Hall SJ, Sehgal I, Wang J, Timme TL, Yang, G Connell-Crowley L, Elledge SJ, Zhang WW, Harper JW, Thompson TC (1995) In vivo gene therapy with p53 or p21 adenovirus for prostate cancer. Cancer Res 55:5151–5155PubMed Eastham JA, Hall SJ, Sehgal I, Wang J, Timme TL, Yang, G Connell-Crowley L, Elledge SJ, Zhang WW, Harper JW, Thompson TC (1995) In vivo gene therapy with p53 or p21 adenovirus for prostate cancer. Cancer Res 55:5151–5155PubMed
go back to reference Ekholm SV, Reed SI (2000) Regulation of G1 cyclin-dependent kinases in the mammalian cell cycle. Curr Opin Cell Biol 12:676–684PubMed Ekholm SV, Reed SI (2000) Regulation of G1 cyclin-dependent kinases in the mammalian cell cycle. Curr Opin Cell Biol 12:676–684PubMed
go back to reference El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B (1993) WAF1, a potential mediator of p53 tumor suppression. Cell 75:817–825PubMed El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B (1993) WAF1, a potential mediator of p53 tumor suppression. Cell 75:817–825PubMed
go back to reference Evan GI, Vousden KH (2001) Proliferation, cell cycle, and apoptosis in cancer. Nature 411:342–348PubMed Evan GI, Vousden KH (2001) Proliferation, cell cycle, and apoptosis in cancer. Nature 411:342–348PubMed
go back to reference Fotedar R, Brickner H, Saadatmandi N, Rousselle T, Diederich L, Munshi A, Jung B, Reed JC, Fotedar A (1999) Effect of p21waf1/cip1 transgene on radiation induced apoptosis in T cells. Oncogene 18:3652–3658CrossRefPubMed Fotedar R, Brickner H, Saadatmandi N, Rousselle T, Diederich L, Munshi A, Jung B, Reed JC, Fotedar A (1999) Effect of p21waf1/cip1 transgene on radiation induced apoptosis in T cells. Oncogene 18:3652–3658CrossRefPubMed
go back to reference Gallagher WM, Brown R (1999) p53-oriented cancer therapies: current progress. Ann Oncol 10:139–150 Gallagher WM, Brown R (1999) p53-oriented cancer therapies: current progress. Ann Oncol 10:139–150
go back to reference Gartel AL, Serfas MS, Tyner AL (1996) p21-negative regulator of the cell cycle. Proc Soc Exp Biol Med 213:138–149PubMed Gartel AL, Serfas MS, Tyner AL (1996) p21-negative regulator of the cell cycle. Proc Soc Exp Biol Med 213:138–149PubMed
go back to reference Gotoh A, Kao HC, Ko SC, Hamada K, Liu TJ, Chung LWK (1997) Cytotoxic effects of recombinant adenovirus p53 and cell cycle regulator genes (p21WAF1/Cip1 and p16CDKN4) in human prostate cancers. J Urol 158:636–641PubMed Gotoh A, Kao HC, Ko SC, Hamada K, Liu TJ, Chung LWK (1997) Cytotoxic effects of recombinant adenovirus p53 and cell cycle regulator genes (p21WAF1/Cip1 and p16CDKN4) in human prostate cancers. J Urol 158:636–641PubMed
go back to reference Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ (1993) The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75:805–816PubMed Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ (1993) The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75:805–816PubMed
go back to reference Herrmann M, Lorenz HM, Voll R, Grunke M, Woith W, Kalden JR (1994) A rapid and simple method for the isolation of apoptotic DNA fragments. Nucleic Acid Res 22:5506–5507PubMed Herrmann M, Lorenz HM, Voll R, Grunke M, Woith W, Kalden JR (1994) A rapid and simple method for the isolation of apoptotic DNA fragments. Nucleic Acid Res 22:5506–5507PubMed
go back to reference Hingorani R, Bi BY, Dao T, Bae Y, Matsuzawa A, Crispe IN (2000) CD95/Fas signaling in T lymphocytes induces the cell cycle control protein p21cip-1/WAF-1, which promotes apoptosis. J Immunol 164:4032–4036PubMed Hingorani R, Bi BY, Dao T, Bae Y, Matsuzawa A, Crispe IN (2000) CD95/Fas signaling in T lymphocytes induces the cell cycle control protein p21cip-1/WAF-1, which promotes apoptosis. J Immunol 164:4032–4036PubMed
go back to reference Hollstein M, Shomer B, Greenblatt M, Soussi T, Hovig E, Montesano R, Harris CC (1996) Somatic point mutations in the p53 gene of human tumors and cell lines: updated compilation. Nucleic Acid Res 24:141–146PubMed Hollstein M, Shomer B, Greenblatt M, Soussi T, Hovig E, Montesano R, Harris CC (1996) Somatic point mutations in the p53 gene of human tumors and cell lines: updated compilation. Nucleic Acid Res 24:141–146PubMed
go back to reference Joshi US, Dergham ST, Chen YQ, Dugan MC, Crissman JD, Vaitkevicius VK, Sarkar FH (1998) Inhibition of pancreatic tumor cell growth in culture by p21WAF1 recombinant adenovirus. Pancreas 16:107–113PubMed Joshi US, Dergham ST, Chen YQ, Dugan MC, Crissman JD, Vaitkevicius VK, Sarkar FH (1998) Inhibition of pancreatic tumor cell growth in culture by p21WAF1 recombinant adenovirus. Pancreas 16:107–113PubMed
go back to reference Katayose D, Wersto R, Cowan KH, Seth P (1995) Effects of a recombinant adenovirus expressing WAF1/Cip1 on cell growth, cell cycle and apoptosis. Cell Growth Differ 6:1207–1212 Katayose D, Wersto R, Cowan KH, Seth P (1995) Effects of a recombinant adenovirus expressing WAF1/Cip1 on cell growth, cell cycle and apoptosis. Cell Growth Differ 6:1207–1212
go back to reference Kralj M, Husnjak K, Körbler T, Pavelić J (2003) Endogenous p21WAF1/CIP1 status predicts the response of human tumor cells to wild-type p53 and p21WAF1/CIP1 overexpression. Cancer Gene Ther 10:457–467 Kralj M, Husnjak K, Körbler T, Pavelić J (2003) Endogenous p21WAF1/CIP1 status predicts the response of human tumor cells to wild-type p53 and p21WAF1/CIP1 overexpression. Cancer Gene Ther 10:457–467
go back to reference Li Z, Rakkar A, Katayose Y, Kim M, Shanmugam N, Srivastava S, Moul JW, McLeod DG, Cowan KH, Seth P (1998) Efficacy of multiple administrations of recombinant adenovirus expressing wild-type p53 in an immune-competent mouse tumor model. Gene Ther 5:605–613CrossRefPubMed Li Z, Rakkar A, Katayose Y, Kim M, Shanmugam N, Srivastava S, Moul JW, McLeod DG, Cowan KH, Seth P (1998) Efficacy of multiple administrations of recombinant adenovirus expressing wild-type p53 in an immune-competent mouse tumor model. Gene Ther 5:605–613CrossRefPubMed
go back to reference Nielsen LL, Maneval DC (1998) p53 tumor suppressor gene therapy for cancer. Cancer Gene Ther 5:52–63PubMed Nielsen LL, Maneval DC (1998) p53 tumor suppressor gene therapy for cancer. Cancer Gene Ther 5:52–63PubMed
go back to reference Nielsen LL, Dell J, Maxwell E, Armstrong L, Maneval D, Catino JJ (1997) Efficacy of p53 adenovirus-mediated gene therapy against human breast cancer xenografts. Cancer Gene Ther 4:129–138PubMed Nielsen LL, Dell J, Maxwell E, Armstrong L, Maneval D, Catino JJ (1997) Efficacy of p53 adenovirus-mediated gene therapy against human breast cancer xenografts. Cancer Gene Ther 4:129–138PubMed
go back to reference Noda A, Ning Y, Venable SF, Pereira-Smith OM, Smith JR (1994) Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp Cell Res 211:90–98CrossRefPubMed Noda A, Ning Y, Venable SF, Pereira-Smith OM, Smith JR (1994) Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp Cell Res 211:90–98CrossRefPubMed
go back to reference Parker LP, Wolf JK, Price JE (2000) Adenoviral-mediated gene therapy with Ad5CMVp53 and Ad5CMVp21 in combination with standard therapies in human breast cancer cell lines. Ann Clin Lab Sci 30:395–405PubMed Parker LP, Wolf JK, Price JE (2000) Adenoviral-mediated gene therapy with Ad5CMVp53 and Ad5CMVp21 in combination with standard therapies in human breast cancer cell lines. Ann Clin Lab Sci 30:395–405PubMed
go back to reference Ramondetta L, Mills GB, Burke TW, Wolf JK (2000) Adenovirus-mediated expression of p53 or p21 in papillary serous endometrial carcinoma cell line (SPEC-2) results in both growth inhibition and apoptotic cell death: potential application of gene therapy to endometrial cancer. Clin Cancer Res 6:278–284PubMed Ramondetta L, Mills GB, Burke TW, Wolf JK (2000) Adenovirus-mediated expression of p53 or p21 in papillary serous endometrial carcinoma cell line (SPEC-2) results in both growth inhibition and apoptotic cell death: potential application of gene therapy to endometrial cancer. Clin Cancer Res 6:278–284PubMed
go back to reference Roninson IB (2002) Oncogenic functions of tumor suppressor p21Waf1/Cip1/Sdi1: association with cell senescence and tumour-promoting activities of stromal fibroblasts. Cancer Lett 179:1–14CrossRefPubMed Roninson IB (2002) Oncogenic functions of tumor suppressor p21Waf1/Cip1/Sdi1: association with cell senescence and tumour-promoting activities of stromal fibroblasts. Cancer Lett 179:1–14CrossRefPubMed
go back to reference Roth JA, Cristiano RJ (1997) Gene therapy for cancer: what have we done and where are we going? J Natl Cancer Inst 89:21–39 Roth JA, Cristiano RJ (1997) Gene therapy for cancer: what have we done and where are we going? J Natl Cancer Inst 89:21–39
go back to reference Sekiguchi T, Hunter T (1998) Induction of growth arrest and cell death by overexpression of the cyclin-Ckd inhibitor p21 in hamster BHK21 cells Oncogene 16:369–380 Sekiguchi T, Hunter T (1998) Induction of growth arrest and cell death by overexpression of the cyclin-Ckd inhibitor p21 in hamster BHK21 cells Oncogene 16:369–380
go back to reference Sheikh MS, Rochefort H, Garcia M (1995) Overexpression of p21 WAF1/CIP1 induces growth arrest, giant cell formation and apoptosis in human breast carcinoma cell lines. Oncogene 11:1899–1905PubMed Sheikh MS, Rochefort H, Garcia M (1995) Overexpression of p21 WAF1/CIP1 induces growth arrest, giant cell formation and apoptosis in human breast carcinoma cell lines. Oncogene 11:1899–1905PubMed
go back to reference Shibata M-A, Yoshidome K, Shibata E, Jorcyk CL, Green JE (2001) Suppression of mammary carcinoma growth in vitro and in vivo by inducible expression of the Cdk inhibitor p21. Cancer Gene Ther 8:23–25CrossRefPubMed Shibata M-A, Yoshidome K, Shibata E, Jorcyk CL, Green JE (2001) Suppression of mammary carcinoma growth in vitro and in vivo by inducible expression of the Cdk inhibitor p21. Cancer Gene Ther 8:23–25CrossRefPubMed
go back to reference Stewart ZA, Pietenpol JA (2001) p53 signaling and cell cycle checkpoints. Chem Res Toxicol 14:243–263CrossRefPubMed Stewart ZA, Pietenpol JA (2001) p53 signaling and cell cycle checkpoints. Chem Res Toxicol 14:243–263CrossRefPubMed
go back to reference Tsao Y-P, Huang S-J, Chang J-L, Hsieh J-T, Pong R-C, Chen S-L (1999) Adenovirus-mediated p21Waf1/Cip1 gene transfer induces apoptosis of human cervical cancer cell lines. J Virol 73:4983–4990PubMed Tsao Y-P, Huang S-J, Chang J-L, Hsieh J-T, Pong R-C, Chen S-L (1999) Adenovirus-mediated p21Waf1/Cip1 gene transfer induces apoptosis of human cervical cancer cell lines. J Virol 73:4983–4990PubMed
go back to reference Wallace-Brodeur RR, Lowe SW (1999) Clinical implications of p53 mutations. Cell Mol Life Sci 55:64–75CrossRefPubMed Wallace-Brodeur RR, Lowe SW (1999) Clinical implications of p53 mutations. Cell Mol Life Sci 55:64–75CrossRefPubMed
go back to reference Yang ZY, Perkins ND, Ohno T, Nabel EG, Nabel GJ (1995) The p21 cyclin-dependent kinase inhibitor suppress tumorigenicity in vivo. Nature Med. 1:1052–1056 Yang ZY, Perkins ND, Ohno T, Nabel EG, Nabel GJ (1995) The p21 cyclin-dependent kinase inhibitor suppress tumorigenicity in vivo. Nature Med. 1:1052–1056
go back to reference Zhang WW (1999) Development and application of adenoviral vectors for gene therapy of cancer. Cancer Gene Ther 6:113–138CrossRefPubMed Zhang WW (1999) Development and application of adenoviral vectors for gene therapy of cancer. Cancer Gene Ther 6:113–138CrossRefPubMed
go back to reference Zhang WW, Fang XM, Mazur W, French BA, Georges RN, Roth JA (1994) High-efficiency gene transfer and high-level expression of wild-type p53 in human lung cancer cells mediated by recombinant adenovirus. Cancer Gene Ther 1:5–13PubMed Zhang WW, Fang XM, Mazur W, French BA, Georges RN, Roth JA (1994) High-efficiency gene transfer and high-level expression of wild-type p53 in human lung cancer cells mediated by recombinant adenovirus. Cancer Gene Ther 1:5–13PubMed
Metadata
Title
p21WAF1/CIP1 is more effective than p53 in growth suppression of mouse renal carcinoma cell line Renca in vitro and in vivo
Authors
Marijeta Kralj
Jasminka Pavelić
Publication date
01-08-2003
Publisher
Springer-Verlag
Published in
Journal of Cancer Research and Clinical Oncology / Issue 8/2003
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-003-0458-2

Other articles of this Issue 8/2003

Journal of Cancer Research and Clinical Oncology 8/2003 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.